Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report issued to clients and investors on Thursday. The firm set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 3.0 %

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.32 on Thursday. The firm’s 50 day moving average is $0.49 and its 200 day moving average is $1.16. The firm has a market capitalization of $19.02 million, a PE ratio of -0.14 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 1 year low of $0.17 and a 1 year high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.